Overview - Oxford Drug Design

At Oxford Drug Design we leverage our knowledge of tRNA synthetases (aaRS) and generative AI methods to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat major diseases where this enzyme family plays a key role.

We focus on identifying novel disease targets based on the non-canonical functions of aaRS and integrate this new biochemistry with our pioneering computational platform trained specifically on this target family.

PIPELINE

Our innovative pipeline is focused initially on oncology first-in-class approaches and is driven by our core competence platform. We have two further therapeutic programs with which we additionally validated this powerful discovery platform.

PLATFORM

We have deep expertise in both aminoacyl-tRNA synthetases (aaRS), and in pioneering computational AI and machine learning methods. The integration of these two complementary strengths produces an even deeper and more differentiated capability.

TECHNOLOGY

Our integrated platform comprises computational drug discovery capabilities for both ligand- and structure-based solutions, with tools that can be configured and applied throughout the pre-clinical development pipeline.